Clinical evaluation data and regulatory authorizations indicate that Pemgarda demonstrates substantial efficacy in providing pre-exposure prophylaxis for the prevention of symptomatic COVID-19 in vulnerable populations, particularly immunocompromised individuals who may not mount an adequate immune response to active vaccination. In vitro neutralization assessments confirm that the therapy maintains targeted activity against circulating viral variants over time. Real-world clinical monitoring and ongoing trials continue to evaluate its effectiveness in reducing infection rates and safeguarding high-risk patients within community settings.